How to buy Oramed Pharmaceuticals stock

Oramed Pharmaceuticals Inc is a biotechnology business based in the US. Oramed Pharmaceuticals shares (ORMP) are listed on the NASDAQ and all prices are listed in US Dollars.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Oramed Pharmaceuticals stock price (NASDAQ: ORMP)

Use our graph to track the performance of ORMP stocks over time.

Oramed Pharmaceuticals shares at a glance

• Key figures

Information last updated 2022-06-24.

Latest market close	$4.56
52-week range	$3.59 - $31.54
50-day moving average more info button	$5.00
200-day moving average more info button	$13.17
Wall St. target price	$31.67
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-1.00

Buy Oramed Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Oramed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oramed Pharmaceuticals price performance over time

Historical closes compared with the close of $4.56 from 2022-06-28

1 week (2022-06-22)	7.80%
1 month (2022-05-27)	-7.13%
3 months (2022-03-28)	-49.78%
6 months (2021-12-29)	-65.19%

1 year (2021-06-29)	-65.92%
2 years (2020-06-29)	30.66%
3 years (2019-06-28)	27.02%
5 years (2017-06-29)	7.63

Oramed Pharmaceuticals financials

Revenue TTM	$2.7 million
Gross profit TTM	$2.7 million
Return on assets TTM	-14.8%
Return on equity TTM	-25.66%
Profit margin	0%
Book value	$4.21
Market capitalisation more info button	$189 million

TTM: trailing 12 months

Oramed Pharmaceuticals share dividends

We're not expecting Oramed Pharmaceuticals to pay a dividend over the next 12 months.

Have Oramed Pharmaceuticals's shares ever split?

Oramed Pharmaceuticals's shares were split on a 1:12 basis on 22 January 2013. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oramed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Oramed Pharmaceuticals shares which in turn could have impacted Oramed Pharmaceuticals's share price.

Oramed Pharmaceuticals share price volatility

Over the last 12 months, Oramed Pharmaceuticals's shares have ranged in value from as little as $3.59 up to $31.54. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oramed Pharmaceuticals's is 2.029. This would suggest that Oramed Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Oramed Pharmaceuticals overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006.

Frequently asked questions

What percentage of Oramed Pharmaceuticals is owned by insiders or institutions?
Currently 4.293% of Oramed Pharmaceuticals shares are held by insiders and 27.069% by institutions. When does the fiscal year end for Oramed Pharmaceuticals?
Oramed Pharmaceuticals's fiscal year ends in August. Where is Oramed Pharmaceuticals based?
Oramed Pharmaceuticals's address is: 1185 Avenue of the Americas, New York, NY, United States, 10036 What is Oramed Pharmaceuticals's ISIN number?
Oramed Pharmaceuticals's international securities identification number is: US68403P2039 What is Oramed Pharmaceuticals's CUSIP number?
Oramed Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 68403P104